TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection

Naoko Iwata‐Yoshikawa(National Institute of Infectious Diseases), Tadashi Okamura(National Center for Global Health and Medicine), Yukiko Shimizu(National Center for Global Health and Medicine), Hideki Hasegawa(National Institute of Infectious Diseases), Makoto Takeda(National Institute of Infectious Diseases), Noriyo Nagata(National Institute of Infectious Diseases)
Journal of Virology
January 10, 2019
Cited by 677

Abstract

Broad-spectrum antiviral drugs against highly pathogenic coronaviruses and other emerging viruses are desirable to enable a rapid response to pandemic threats. Transmembrane protease serine type 2 (TMPRSS2), a protease belonging to the type II transmembrane serine protease family, cleaves the coronavirus spike protein, making it a potential therapeutic target for coronavirus infections. Here, we examined the role of TMPRSS2 using animal models of SARS-CoV and MERS-CoV infection. The results suggest that lack of TMPRSS2 in the airways reduces the severity of lung pathology after infection by SARS-CoV and MERS-CoV. Taken together, the results will facilitate development of novel targets for coronavirus therapy.


Related Papers

No related papers found

Powered by citation graph analysis